EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Harnessing the Gut Microbiome in Cancer Immunotherapy: Mechanisms, Challenges, and Routes to Personalized Medicine—A Systematic Review

Amir Dayhimi iD, Kimia Jazi iD, Asiye Bigdeli iD, Fatemeh Farhoudi, Mohamadreza Erfanimanesh, Mina Esmaeili iD, Farhad Gorjipour, Marjan Ajami iD, Hamidreza Pazoki-Toroudi iD

Technology in Cancer Research & Treatment · 2025-06 · 24

DOI: 10.1177/15330338251365700 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 28.08.2025. Verfasst von Amir Dayhimi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Neoplasms, Immunotherapy, Probiotics. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immunotherapy approaches have improved by Immune check point inhibitors such as PD-1, CTLA-4, and PD-L1 inhibitors. However, the response to immunotherapy varies widely among patients due to various factors. Co-administration of probiotics with ICIs has become a promising strategy to improve therapeutic outcomes. This review evaluates the impact of environmental factors and life style on cancer pathophysiology, outcome of disease, and response to the treatment. It evaluates the role of probiotics in modulating immune responses and the synergistic interaction of probiotics with immunotherapy.

Methods

We conducted a comprehensive systematic review of clinical and preclinical studies to assess the effects of probiotics on immunotherapy outcomes. Studies were selected based on their focus on probiotics’ role in immune response modulation and interaction with ICIs. Data from trials involving patients with varying responses to immunotherapy, including those with prior resistance, were analyzed to explore the probiotic-enhanced immunotherapy.

Results

Gut microbiome has wide effects on immune responses through different pathways like production of short chain fatty acids (SCFAs), polysaccharide A, and indole-3-carbaldehyde. Also, probiotics found to enhance Anit-inflammatory responses and increase CD8+ T-cell activity, suggesting a synergistic effect with ICIs. Gut microbiota composition plays a key role in determining the effectiveness of immunotherapy, especially in treatment-resistant patients. For optimized treatment outcomes, personalized probiotics tailored to individual's microbiota showed potential. Important challenges are treatment resistance and compromised mucosal integrity because of microbiome alterations. Effective drug delivery also remains as important barriers to common adoption.

Conclusion

For immunotherapy outcomes improvement, immune responses modulation and gut microbiome diversity enhancement show probiotics important promise. Despite their potential, limitations must be addressed including treatment resistance and also delivery challenges. In order to maximize therapeutic benefits, personalized probiotic strategies have to be developed, and also the mechanisms by which probiotics improve ICI efficacy require elucidation through further research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeNeoplasmsImmunotherapyProbioticsPrecision MedicineHumansImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

SCFAimmune checkpoint inhibitors (ICIs)immunotherapyindole-3-carbaldehydemicrobiomepersonalized medicinepolysaccharide Aprobiotics

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Iranian Tissue Bank and Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Student Research Committee, Faculty of Medicine, Qom University of Medical Sciences, Qom, Iran.
  • Department of Food Science and Technology, National Nutrition and Food Technology Research Institute, Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Amir Dayhimi, Kimia Jazi, Asiye Bigdeli, Mina Esmaeili, Marjan Ajami, Hamidreza Pazoki-Toroudi

Zitieren

APA

Dayhimi, A., Jazi, K., Bigdeli, A., Farhoudi, F., Erfanimanesh, M., Esmaeili, M., Gorjipour, F., Ajami, M., & Pazoki-Toroudi, H. (2025). Harnessing the Gut Microbiome in Cancer Immunotherapy: Mechanisms, Challenges, and Routes to Personalized Medicine—A Systematic Review. Technology in Cancer Research & Treatment, 24. https://doi.org/10.1177/15330338251365700

Vancouver

Dayhimi A, Jazi K, Bigdeli A, Farhoudi F, Erfanimanesh M, Esmaeili M, et al. Harnessing the Gut Microbiome in Cancer Immunotherapy: Mechanisms, Challenges, and Routes to Personalized Medicine—A Systematic Review. Technology in Cancer Research & Treatment. 2025;24. doi:10.1177/15330338251365700

BibTeX
@article{Dayhimi2025,
  author = {Dayhimi, Amir and Jazi, Kimia and Bigdeli, Asiye and Farhoudi, Fatemeh and Erfanimanesh, Mohamadreza and Esmaeili, Mina and Gorjipour, Farhad and Ajami, Marjan and Pazoki-Toroudi, Hamidreza},
  title = {Harnessing the Gut Microbiome in Cancer Immunotherapy: Mechanisms, Challenges, and Routes to Personalized Medicine—A Systematic Review},
  journal = {Technology in Cancer Research & Treatment},
  year = {2025},
  volume = {24},
  doi = {10.1177/15330338251365700}
}
Kostenlos starten →